The management of stroke classically relies on clinical assessment and neurological imaging methods, imposing a need for more time-sensitive techniques such as point-of-care tests capable of detecting specific stroke biomarkers such as B-type Natriuretic Peptide (BNP) for suspected ischemic stroke, neuron specific enolase (NSE), fibronectin for hemorrhagic stroke, and purines (e.g., adenosine, inosine and hypoxanthine) released after stroke onset [37,38,39,40]. The gene discussed is ENO2; the disease is ischemic stroke.